Cell‐derived microparticles, which are recognized as nanosized phospholipid bilayer membrane vesicles, have exhibited great potential to serve as drug delivery systems in cancer therapy. However, for the purpose of comprehensive therapy, microparticles decorated with multiple therapeutic components are needed, but effective engineering strategies are limited and still remain enormous challenges. Herein, Bi2Se3 nanodots and doxorubicin hydrochloride (DOX) co‐embedded tumor cell‐derived microparticles (Bi2Se3/DOX@MPs) are successfully constructed through ultraviolet light irradiation‐induced budding of parent cells which are preloaded with Bi2Se3 nanodots and DOX via electroporation. The multifunctional microparticles are obtained with high controllability and drug‐loading capacity without unfavorable membrane surface destruction, maintaining their excellent intrinsic biological behaviors. Through membrane fusion cellular internalization, Bi2Se3/DOX@MPs show enhanced cellular internalization and deepened tumor penetration, resulting in extreme cell damage in vitro without considering endosomal escape. Because of their distinguished photothermal performance and tumor homing target capability, Bi2Se3/DOX@MPs exhibit admirable dual‐modal imaging capacity and outstanding tumor suppression effect. Under 808 nm laser irradiation, intravenous injection of Bi2Se3/DOX@MPs into H22 tumor‐bearing mice results in remarkably synergistic antitumor efficacy by combining photothermal therapy with low‐dose chemotherapy in vivo. Furthermore, the negligible hemolytic activity, considerable metabolizability, and low systemic toxicity of Bi2Se3/DOX@MPs imply their distinguished biocompatibility and great potential for tumor theranostics.
In the present study, a kind of single-hole glutathione (GSH)-responsive degradable hollow silica nanoparticles (G-DHSNs) was synthesized and used as carriers of doxorubicin (DOX) (DOX-G-DHSNs). The G-DHSNs were accurately designed and fabricated with a simple and convenient method, and without any extra pernicious component. The composition, morphology and properties of the G-DHSNs had been characterized by (1)HNMR spectra, Fourier transform infrared spectrograph, thermo gravimetric analysis, transmission electron microscope, and scanning electron microscope. The degradation study of G-DHSNs showed that the G-DHSNs would be broken into pieces after interacting with GSH. Besides, the negligible hemolytic activity and low cytotoxicity of the G-DHSNs demonstrated its excellent biocompatibility. pH- and GSH-triggered release of DOX followed by the decomposition of G-DHSNs within TCA8113 cancer cells was further confirmed by flow cytometry and confocal laser scanning microscopy studies. All of these results indicated that G-DHSNs can be used as safe and promising drug nanocarriers.
We present here a novel camptothecin (CPT) prodrug based on polyethylene glycol monomethyl ether-block-poly(2-methacryl ester hydroxyethyl disulfide-graft-CPT) (MPEG-SS-PCPT). It formed biocompatible nanoparticles (NPs) with diameters of approximately 122 nm with a CPT loading content as high as approximately 25 wt% in aqueous solution. In in vitro release studies, these MPEG-SS-PCPT NPs could undergo triggered disassembly and much faster release of CPT under glutathione (GSH) stimulus than in the absence of GSH. The CPT prodrug had high antitumor activity, and another anticancer drug, doxorubicin hydrochloride (DOX⋅HCl), could also be introduced into the prodrug with a high loading amount. The DOX·HCl-loaded CPT prodrug could deliver two anticancer drugs at the same time to produce a collaborative cytotoxicity toward cancer cells, which suggested that this GSH-responsive NP system might become a promising carrier to improve drug-delivery efficacy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.